The potential of noninvasive brain stimulation techniques for the treatment of central nervous system demyelinating diseases: a narrative review
Advanced technology in neuroscience .,
Journal Year:
2024,
Volume and Issue:
1(2), P. 211 - 228
Published: Nov. 27, 2024
Noninvasive
brain
stimulation
techniques
have
emerged
as
a
promising
therapeutic
option
for
various
central
nervous
system
demyelinating
diseases.
Demyelinating
diseases
represent
group
of
pathological
conditions
that
impact
the
or
peripheral
system.
They
are
characterized
by
damage
to
loss
myelin
sheath
surrounding
nerve
fibers.
This
sheaths
disrupts
signal
transmission,
leading
wide
range
signs
and
symptoms
associated
with
neurological
impairment.
Treatment
usually
aligns
specific
underlying
cause.
can
affect
neuronal
electrical
activity
glial
cell
function,
suggesting
potential
intervention.
In
this
narrative
review,
we
explore
noninvasive
treatment
disorders.
techniques,
including
transcranial
magnetic
stimulation,
focused
ultrasound
optogenetic
low-intensity
pulsed
ultrasound,
photobiomodulation,
been
shown
potentially
intervene
in
affecting
cells
function.
addition,
review
summarizes
applications
mechanisms
how
these
promote
regeneration
improve
disease
prognosis.
also
research
advances
multiple
sclerosis,
acute
disseminated
encephalomyelitis,
progressive
multifocal
leukoencephalopathy,
neuromyelitis
optical
spectrum
disorder.
promoting
oligodendrocyte
proliferation
differentiation,
enhancing
regeneration,
modulating
immune
responses.
Although
disorders,
their
use
treating
remains
challenging.
For
example,
is
relatively
new
technique
advantages
high
spatial
resolution
ability
stimulate
deep
structures,
but
its
safety
efficacy
clinical
need
be
further
investigated.
Optogenetic
offers
highly
precise
neuromodulation,
feasibility
practice
limited
technical
ethical
constraints.
Overall,
significant
diseases,
needed
optimize
parameters,
efficacy,
gain
insight
into
mechanism
action.
With
continuous
development
technology
in-depth
trials,
expected
become
an
effective
provide
options
such
patients.
Language: Английский
ALSUntangled #77: Psilocybin
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 4
Published: Dec. 22, 2024
ALSUntangled
reviews
alternate
and
off-label
treatments
prompted
by
patient
interest.
Here,
we
review
psilocybin,
a
chemical
derived
from
mushrooms
belonging
in
the
category
of
drugs
known
as
psychedelics.
Psilocybin
has
plausible
mechanisms
for
slowing
ALS
progression
because
its
ability
to
cross
blood
brain
barrier
effect
neurogenesis
inflammation.
Currently,
there
are
no
pre-clinical
models,
case
reports,
or
trials
psilocybin
context
disease
modifying
therapy.
Depending
on
dosing,
can
be
high
risk
psychological
side
effects
including
hallucinations
physical
harm.
Based
above
information,
do
not
currently
support
use
means
slow
progression.
Language: Английский